{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:27:19Z","timestamp":1792207639617,"version":"4.4.0"},"reference-count":25,"publisher":"American Society of Hematology","issue":"19","license":[{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10,8]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>The Blood and Marrow Transplant (BMT) Clinical Trials Network conducted a phase 3 randomized trial comparing gilteritinib with placebo after allogeneic hematopoietic cell transplantation (HCT) for\u00a0FLT3-ITD+\u00a0acute myeloid leukemia (AML). The primary analysis demonstrated no statistically significant difference in relapse-free survival (RFS); however, patients with\u00a0FLT3-ITD\u00a0measurable residual disease (MRD) peri-HCT had significantly longer RFS with gilteritinib. This analysis investigates the effect of post-HCT gilteritinib vs placebo on health-related quality of life (HRQOL). HRQOL was measured with Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT), FACT-Leukemia (FACT-Leu), and EuroQOL-5 Dimensions (EQ-5D-5L) at post-HCT randomization; day 29; months 3, 6, 12, 18, 24; and\/or end of therapy. HRQOL and clinically meaningful differences were summarized using descriptive statistics and compared using mixed model repeated measures to evaluate longitudinal change from baseline and stratified Cox model to evaluate time to improvement. HRQOL completion rate was acceptable (&amp;gt;70%) across all time points and measures. There were no differences in HRQOL scores at any time point between cohorts. Clinically meaningful and time to improvement in HRQOL were similar in both arms. Despite higher treatment-emergent adverse effects with gilteritinib, response to the question of being \u201cbothered by side effects of treatment\u201d did not differ between groups. Subgroup analysis of MRD-positive and negative patients demonstrated no differences in HRQOL between arms. For patients with\u00a0FLT3-ITD+\u00a0AML undergoing HCT, gilteritinib maintenance was not associated with any difference in HRQOL or patient-reported impact of side effects. This trial was registered at www.ClinicalTrials.gov as #NCT02997202.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013746","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T02:27:14Z","timestamp":1724293634000},"page":"5091-5099","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["Health-related quality of life with gilteritinib vs placebo posttransplant for <i>FLT3-ITD<\/i>\n                  <i>+<\/i> acute myeloid leukemia"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1252-6539","authenticated-orcid":false,"given":"Betty K.","family":"Hamilton","sequence":"first","affiliation":[{"name":"1Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4437-7457","authenticated-orcid":false,"given":"Bhavik J.","family":"Pandya","sequence":"additional","affiliation":[{"name":"2Astellas, Northbrook, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Ivanescu","sequence":"additional","affiliation":[{"name":"3IQVIA, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Elsouda","sequence":"additional","affiliation":[{"name":"2Astellas, Northbrook, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5372-510X","authenticated-orcid":false,"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[{"name":"4Division of Hematology and Oncology, Department of Medicine, Medical College of Wisoncsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9554-1058","authenticated-orcid":false,"given":"Yi-Bin","family":"Chen","sequence":"additional","affiliation":[{"name":"5Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0473-6982","authenticated-orcid":false,"given":"Mark J.","family":"Levis","sequence":"additional","affiliation":[{"name":"6Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2277-1976","authenticated-orcid":false,"given":"Masumi","family":"Ueda Oshima","sequence":"additional","affiliation":[{"name":"7Cancer Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA"},{"name":"16Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9816-6302","authenticated-orcid":false,"given":"Mark R.","family":"Litzow","sequence":"additional","affiliation":[{"name":"8Division of Hematology and Transplant Center, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Soiffer","sequence":"additional","affiliation":[{"name":"9Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6896-6213","authenticated-orcid":false,"given":"Celalettin","family":"Ustun","sequence":"additional","affiliation":[{"name":"10Division of Hematology Oncology and Cell Therapy, Rush University Medical Center, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1463-2231","authenticated-orcid":false,"given":"Alexander E.","family":"Perl","sequence":"additional","affiliation":[{"name":"11Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurag K.","family":"Singh","sequence":"additional","affiliation":[{"name":"12Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0500-7386","authenticated-orcid":false,"given":"Nancy","family":"Geller","sequence":"additional","affiliation":[{"name":"13Office of Biostatistics Research, National Heart, Lung, and Bood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahla","family":"Hasabou","sequence":"additional","affiliation":[{"name":"2Astellas, Northbrook, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Rosales","sequence":"additional","affiliation":[{"name":"2Astellas, Northbrook, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cella","sequence":"additional","affiliation":[{"name":"14Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Corredoira","sequence":"additional","affiliation":[{"name":"15IQVIA, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8421-6965","authenticated-orcid":false,"given":"Carolina","family":"Pestana","sequence":"additional","affiliation":[{"name":"15IQVIA, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary M.","family":"Horowitz","sequence":"additional","affiliation":[{"name":"4Division of Hematology and Oncology, Department of Medicine, Medical College of Wisoncsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent","family":"Logan","sequence":"additional","affiliation":[{"name":"4Division of Hematology and Oncology, Department of Medicine, Medical College of Wisoncsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"issue":"7","key":"2024100813060235000_bib1","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.bbmt.2020.03.002","article-title":"Indications for hematopoietic cell transplantation and immune effector cell therapy: guidelines from the American Society for Transplantation and Cellular Therapy","volume":"26","author":"Kanate","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2024100813060235000_bib2","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2024100813060235000_bib3","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.bbmt.2020.09.020","article-title":"Hematopoietic cell transplantation in the treatment of newly diagnosed adult acute myeloid leukemia: an evidence-based review from the American Society of Transplantation and Cellular Therapy","volume":"27","author":"Dholaria","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"26","key":"2024100813060235000_bib4","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2024100813060235000_bib5","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41409-020-01153-1","article-title":"Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia","volume":"56","author":"Maziarz","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"2024100813060235000_bib6","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/S1470-2045(20)30455-1","article-title":"Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial","volume":"21","author":"Xuan","year":"2020","journal-title":"Lancet Oncol"},{"issue":"12","key":"2024100813060235000_bib7","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/j.bbmt.2014.09.007","article-title":"Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia","volume":"20","author":"Chen","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"2024100813060235000_bib8","doi-asserted-by":"crossref","first-page":"1095870","DOI":"10.3389\/fonc.2023.1095870","article-title":"Real-world experience of sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for FLT3-ITD AML reveals high rates of toxicity-related treatment interruption","volume":"13","author":"Morin","year":"2023","journal-title":"Front Oncol"},{"issue":"2","key":"2024100813060235000_bib9","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.bbmt.2019.09.023","article-title":"A\u00a0prospective study of peritransplant sorafenib for patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic transplantation","volume":"26","author":"Pratz","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"15","key":"2024100813060235000_bib10","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.23.02474","article-title":"Gilteritinib as post-transplant maintenance for acute myeloid leukemia with internal tandem duplication mutation of FLT3","volume":"42","author":"Levis","year":"2024","journal-title":"J Clin Oncol"},{"issue":"5","key":"2024100813060235000_bib11","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1046\/j.1524-4733.2003.65309.x","article-title":"Incorporating the patient\u2019s perspective into drug development and communication: an ad hoc task force report of the Patient-Reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration","volume":"6","author":"Acquadro","year":"2003","journal-title":"Value Health"},{"issue":"4","key":"2024100813060235000_bib12","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/sj.bmt.1700672","article-title":"Quality of life measurement in bone marrow transplantation: development of the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) scale","volume":"19","author":"McQuellon","year":"1997","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2024100813060235000_bib13","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/0163278705275341","article-title":"General population and cancer patient norms for the Functional Assessment of Cancer Therapy-General (FACT-G)","volume":"28","author":"Brucker","year":"2005","journal-title":"Eval Health Prof"},{"issue":"8","key":"2024100813060235000_bib14","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jval.2012.08.2210","article-title":"Measuring health-related quality of life in leukemia: the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu) questionnaire","volume":"15","author":"Cella","year":"2012","journal-title":"Value Health"},{"issue":"3","key":"2024100813060235000_bib15","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00005650-200503000-00003","article-title":"US valuation of the EQ-5D health states: development and testing of the D1 valuation model","volume":"43","author":"Shaw","year":"2005","journal-title":"Med Care"},{"key":"2024100813060235000_bib16","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1477-7525-1-79","article-title":"The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: properties, applications, and interpretation","volume":"1","author":"Webster","year":"2003","journal-title":"Health Qual Life Outcomes"},{"issue":"2","key":"2024100813060235000_bib17","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1177\/0163278705275340","article-title":"Combining distribution- and anchor-based approaches to determine minimally important differences: the FACIT experience","volume":"28","author":"Yost","year":"2005","journal-title":"Eval Health Prof"},{"issue":"5","key":"2024100813060235000_bib18","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/01.MLR.0000062554.74615.4C","article-title":"Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation","volume":"41","author":"Norman","year":"2003","journal-title":"Med Care"},{"issue":"2","key":"2024100813060235000_bib19","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3816\/CLC.2009.n.010","article-title":"Importance of quality of life in patients with non-small-cell lung cancer","volume":"10","author":"Camps","year":"2009","journal-title":"Clin Lung Cancer"},{"issue":"11","key":"2024100813060235000_bib20","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1097\/JTO.0b013e318267cf84","article-title":"Safety, resource use, and quality of life in paramount: a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer","volume":"7","author":"Gridelli","year":"2012","journal-title":"J\u00a0Thorac Oncol"},{"issue":"5","key":"2024100813060235000_bib21","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/ejh.13379","article-title":"Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: the TOURMALINE-MM3 trial","volume":"104","author":"Schjesvold","year":"2020","journal-title":"Eur J Haematol"},{"key":"2024100813060235000_bib22","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.2147\/PPA.S421871","article-title":"Patient and physician preferences for acute myeloid leukemia maintenance treatments following hematopoietic stem cell transplantation","volume":"17","author":"Saini","year":"2023","journal-title":"Patient Prefer Adherence"},{"issue":"9","key":"2024100813060235000_bib23","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1182\/blood-2012-09-451872","article-title":"A\u00a0randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial","volume":"121","author":"Stewart","year":"2013","journal-title":"Blood"},{"issue":"14","key":"2024100813060235000_bib24","doi-asserted-by":"crossref","first-page":"12897","DOI":"10.1007\/s00432-023-05137-8","article-title":"A\u00a0patient survey indicates quality of life and progression-free survival as equally important outcome measures in multiple myeloma clinical trials","volume":"149","author":"Fleischer","year":"2023","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"18","key":"2024100813060235000_bib25","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1002\/cncr.28758","article-title":"Ambulatory cancer and US general population reference values and cutoff scores for the functional assessment of cancer therapy","volume":"120","author":"Pearman","year":"2014","journal-title":"Cancer"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/19\/5091\/2245610\/blooda_adv-2024-013746-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/19\/5091\/2245610\/blooda_adv-2024-013746-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T16:23:41Z","timestamp":1728404621000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/19\/5091\/517514\/Health-related-quality-of-life-with-gilteritinib"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":25,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2024,10,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013746","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,27]]}}}